SOMNOMED FRANCE : revenue, balance sheet and financial ratios

SOMNOMED FRANCE is a French company founded 14 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in ANCENIS-SAINT-GEREON (44150), this company of category PME shows in 2025 a revenue of 7.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SOMNOMED FRANCE (SIREN 534084009)
Indicator 2025 2024 2023 2021 2020 2019 2018 2017 2016
Revenue 7 240 200 € 6 096 625 € 5 014 547 € 3 296 694 € 2 236 091 € 2 061 315 € 1 237 466 € 831 838 € 632 010 €
Net income 266 133 € 202 774 € 247 030 € 128 215 € 31 312 € 78 987 € -470 903 € -438 304 € -344 632 €
EBITDA 299 369 € 258 674 € 192 095 € -11 855 € -81 382 € -152 318 € -664 054 € -607 229 € -92 589 €
Net margin 3.7% 3.3% 4.9% 3.9% 1.4% 3.8% -38.1% -52.7% -54.5%

Revenue and income statement

In 2025, SOMNOMED FRANCE achieves revenue of 7.2 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +31.1%. Vs 2024, growth of +19% (6.1 M€ -> 7.2 M€). After deducting consumption (3.1 M€), gross margin stands at 4.1 M€, i.e. a rate of 57%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 299 k€, representing 4.1% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 266 k€, i.e. 3.7% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

7 240 200 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

4 138 522 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

299 369 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

271 885 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

266 133 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

4.1%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at -35%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -16%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.4 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 4.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

-34.566%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

-16.483%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

4.055%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.44

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

42.6%

Solvency indicators evolution
SOMNOMED FRANCE

Sector positioning

Debt ratio
-34.57 2025
2023
2024
2025
Q1: 5.49
Med: 17.07
Q3: 41.92
Excellent

In 2025, the debt ratio of SOMNOMED FRANCE (-34.57) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
-16.48% 2025
2023
2024
2025
Q1: 36.67%
Med: 56.53%
Q3: 69.09%
Watch -6 pts over 3 years

In 2025, the financial autonomy of SOMNOMED FRANCE (-16.5%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Repayment capacity
0.44 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.66 years
Q3: 1.52 years
Good -24 pts over 3 years

In 2025, the repayment capacity of SOMNOMED FRANCE (0.44) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 60.68. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.0x. Coverage is limited: any activity downturn would jeopardize interest payments.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

60.677

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

1.982

Liquidity indicators evolution
SOMNOMED FRANCE

Sector positioning

Liquidity ratio
60.68 2025
2023
2024
2025
Q1: 181.98
Med: 251.18
Q3: 365.98
Watch

In 2025, the liquidity ratio of SOMNOMED FRANCE (60.68) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
1.98x 2025
2023
2024
2025
Q1: 0.0x
Med: 0.83x
Q3: 3.14x
Good -9 pts over 3 years

In 2025, the interest coverage of SOMNOMED FRANCE (2.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 8 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 132 days. Excellent situation: suppliers finance 124 days of the operating cycle (retail model). Inventory turnover is 9 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. WCR is negative (-18 days): operations structurally generate cash. Notable WCR improvement over the period (-1345%), freeing up cash.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

-354 842 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

8 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

132 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

9 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

-18 j

WCR and payment terms evolution
SOMNOMED FRANCE

Positioning of SOMNOMED FRANCE in its sector

Comparison with sector Fabrication de matériel médico-chirurgical et dentaire

Valuation estimate

Based on 57 transactions of similar company sales (all years), the value of SOMNOMED FRANCE is estimated at 1 034 838 € (range 341 324€ - 2 053 340€). With an EBITDA of 299 369€, the sector multiple of 2.5x is applied. The price/revenue ratio is 0.23x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2025
57 tx
341k€ 1034k€ 2053k€
1 034 838 € Range: 341 324€ - 2 053 340€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
299 369 € × 2.5x
Estimation 760 206 €
149 408€ - 1 405 865€
Revenue Multiple 30%
7 240 200 € × 0.23x
Estimation 1 642 080 €
763 158€ - 3 435 774€
Net Income Multiple 20%
266 133 € × 3.0x
Estimation 810 556 €
188 363€ - 1 598 380€
How is this estimate calculated?

This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de matériel médico-chirurgical et dentaire)

Compare SOMNOMED FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire

Frequently asked questions about SOMNOMED FRANCE

What is the revenue of SOMNOMED FRANCE ?

The revenue of SOMNOMED FRANCE in 2025 is 7.2 M€.

Is SOMNOMED FRANCE profitable?

Yes, SOMNOMED FRANCE generated a net profit of 266 k€ in 2025.

Where is the headquarters of SOMNOMED FRANCE ?

The headquarters of SOMNOMED FRANCE is located in ANCENIS-SAINT-GEREON (44150), in the department Loire-Atlantique.

Where to find the tax return of SOMNOMED FRANCE ?

The tax return of SOMNOMED FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SOMNOMED FRANCE operate?

SOMNOMED FRANCE operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.